TNF-α Inhibitors in Combination with MTX Reduce Circulating Levels of Heparan Sulfate/Heparin and Endothelial Dysfunction Biomarkers (sVCAM-1, MCP-1, MMP-9 and ADMA) in Women with Rheumatoid Arthritis.

MLA

Szeremeta, Anna, et al. “TNF-α Inhibitors in Combination with MTX Reduce Circulating Levels of Heparan Sulfate/Heparin and Endothelial Dysfunction Biomarkers (SVCAM-1, MCP-1, MMP-9 and ADMA) in Women with Rheumatoid Arthritis.” Journal of Clinical Medicine, vol. 11, no. 14, July 2022, p. 4213. EBSCOhost, https://doi.org/10.3390/jcm11144213.

APA

Szeremeta, A., Jura-Półtorak, A., Zoń-Giebel, A., Olczyk, K., & Komosińska-Vassev, K. (2022). TNF-α Inhibitors in Combination with MTX Reduce Circulating Levels of Heparan Sulfate/Heparin and Endothelial Dysfunction Biomarkers (sVCAM-1, MCP-1, MMP-9 and ADMA) in Women with Rheumatoid Arthritis. Journal of Clinical Medicine, 11(14), 4213. https://doi.org/10.3390/jcm11144213

Chicago

Szeremeta, Anna, Agnieszka Jura-Półtorak, Aleksandra Zoń-Giebel, Krystyna Olczyk, and Katarzyna Komosińska-Vassev. 2022. “TNF-α Inhibitors in Combination with MTX Reduce Circulating Levels of Heparan Sulfate/Heparin and Endothelial Dysfunction Biomarkers (SVCAM-1, MCP-1, MMP-9 and ADMA) in Women with Rheumatoid Arthritis.” Journal of Clinical Medicine 11 (14): 4213. doi:10.3390/jcm11144213.